Everyday Health on MSN

Reversing prediabetes could slash heart disease risk

New findings suggest that for people with prediabetes, normalizing blood sugar levels can help prevent heart disease. Learn ...
MedPage Today

Smart Pill Bottle Boosts Adherence to Endocrine Therapy in Early Breast Cancer

At the San Antonio Breast Cancer Symposium, researchers reported that real-time monitoring with smart pill bottles ...
The American Journal of Managed Care

Breast Cancer Survivors Benefit From Tailored, Team-Based Menopause Care

Menopause after breast cancer can cause symptoms that substantially impact quality of life, making individualized, multidisciplinary care and shared decision-making critical, experts noted during ...

8 Menopause Symptoms Women May Not Recognize and Shouldn't Ignore

Most women begin the menopausal transition in their 40s and 50s, but some can have symptoms in their 30s. Mayo Clinic doctors ...

Understanding hypoparathyroidism: A rare endocrine disorder explained by Dr. Robert Busch

Hypoparathyroidism, a rare and chronic endocrine disease, is characterized by insufficient levels of parathyroid hormone (PTH ...
rarediseaseadvisor

Premature Ovarian Insufficiency May Be an Endocrine Feature of MTDPS1

A case of mitochondrial DNA depletion syndrome 1 (MTDPS1), a condition similar to thymidine kinase 2 deficiency (TK2d), presented with premature ovarian insufficiency (POI), according to a recent ...
Labroots

Alleviating Symptoms Associated with Breast Cancer Endocrine Therapies

About two thirds of breast cancers are classified as “hormone receptor positive” disease. These cancer cells express a group of proteins that bind to hormones, including estrogen and progesterone, ...
Too Old to Operate

ASCO: Elinzanetant Cuts Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

TUESDAY, June 3, 2025 (HealthDay News) — For women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for hormone receptor (HR)-positive breast cancer, elinzanetant, a ...
MarketWatch

Elinzanetant Significantly Reduces Frequency of Moderate to Severe Vasomotor Symptoms Associated With Endocrine Therapy for Breast Cancer in Phase III Oasis-4 Study - MarketWatch

The MarketWatch News Department was not involved in the creation of this content. Data from Phase III OASIS-4 study to be presented for the first time at 2025 ASCO Annual Meeting: -- In the Phase III ...
The New England Journal of Medicine

Elinzanetant for Vasomotor Symptoms from Endocrine Therapy

In this trial involving women taking endocrine therapy for HR-positive breast cancer, elinzanetant (a neurokinin-targeted therapy) significantly reduced the frequency of moderate-to-severe vasomotor ...
Morningstar

Sermonix Announces Clinical Breast Cancer Publication of Article Examining Effects of Lasofoxifene Versus Fulvestrant on Urogenital Symptoms in Patients with ESR1-Mutated ER+ ...

The currently enrolling Phase 3, registrational, ELAINE-3 trial (NCT05696626) comparing the efficacy and safety of lasofoxifene plus abemaciclib to fulvestrant plus abemaciclib will incorporate the ...
Business Insider

Sermonix Announces Clinical Breast Cancer Publication of Article Examining Effects of Lasofoxifene Versus Fulvestrant on Urogenital Symptoms in Patients with ESR1-Mutated ER+ ...

COLUMBUS, Ohio, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast ...